Thermo Fisher to Buy Life Technologies for $13.6 Billion in Bid to Beef Up Its Share of Next-Generation Genetic Testing Market

Multi-billion-dollar mega-deal positions Thermo Fisher to offer a broader spectrum of gene sequencing systems to clinical laboratories and pathology groups Earlier this week, Thermo Fisher Scientific, Inc., (NYSE: TMO) of Waltham, Massachusetts, announced a deal that will shake up the market for next-generation gene sequencing and genetic testing. It will acquire Life Technologies Corporation (NASDAQ: LIFE) of Carlsbad, California. More IVD Industry Consolidation That Affects Clinical...

Is Whole-genome Sequencing Reaching a Tipping Point for Clinical Pathology Laboratories?

High-Density Sequencing Chips Will Soon Be Able To Sequence Five Million SNPs Rapid gene sequencing is catching the interest of progressive anatomic pathologists. These medical laboratory professionals are interested in using rapid gene sequencing technology to allow them to study tens and hundreds of genes on a patient specimen. The technologies used in rapid gene sequencing are being developed and improved by a handful of biotech companies who are racing each other be first to deliver...
;